| |
|
|
| |
Dry Powder Inhalation
Technology, Devices, Markets and
Opportunities
|
Publication: January 2012
Product Code: DPD844R
|
Advances in drug formulation and inhalation device design
are creating new opportunities for inhaled drug delivery as
an alternative to oral and parenteral delivery methods. Much
of the interest in pulmonary delivery of systemic drug
therapies is focused on chronic diseases and refractory
conditions – aliments that require frequent drug
administration for a protracted period of time. While
several approaches for delivering active substances to, and
systematically via, the lungs compete in this space, recent
advances and investment in powder formulations, particle
engineering, and device architecture have positioned dry
powder inhalation (DPI) as a formidable challenger to more
established pulmonary methods such as metered dose inhalers
and nebulizers. While evolving DPI technology and
combination therapeutic products continue to have a
significant impact on the treatment of upper respiratory
diseases and conditions, dry powder inhalers are making
strides in applications requiring the systemic delivery of
both small and large molecule and engineered macromolecules
for the treatment of a range of pathologies. |
|
Highlights |
· Analyzes and evaluates
Dry Powder Inhalers and competing inhaled drug delivery
technologies and assesses the market potential for
existing and probable future products
· Examines Dry Powder
Inhaler design issues and evolving market factors
· Forecasts the impact of
DPI technology and devices on drug delivery markets and
projects probable future developments
· Provides forecasts of DPI combination
product demand by indication and drug class to 2016
• Profiles Dry Powder Inhalation market participants,
their technology, product development activity, and
business strategies
|
|
Summary of Contents |
Executive Summary
The Market Picture for
Inhaled Therapeutics
Devices, Formulations
and Market Evolution
Established Therapeutic
Targets
Emerging Therapies
Demographics and
Growth
Competing Technologies
Market Drivers
Risk Factors
Dry Powder Inhalation Technology
Dry Powder Formulations
Dry Powder Particle
Technology & Powder Engineering
Dry Powder
Formulations
Dry Powder Processing
Dry Powder
Packaging
Emerging Formulations
Dry Powder
Inhalers
DPI Device Characteristics
DPI Design
Parameters
DPI Device Assessments
Acu-Breathe
(Respirics)
Aerolizer Novartis)
AIR (Civitas/Alkermes)
Airmax (Teva)
Aspirair (Vectura)
Axahaler
(S.M.B.)
Breezhaler (Novartis)
Clickhaler (Vectura)
Conix Dry (3M)
Cricket (Mannkind)
Cyclohaler (Teva)
Diskhaler (GlaxoSmithKline)
Diskus
(GlaxoSmithKline)
Dreamboat (Mannkind)
Easyhaler (Orion)
EZ Aer (Aerovance)
Flexhaler
(AstraZeneca)
Genuair (Almirall)
Gemini (GSK)
Handihaler Boehringer Ingelheim)
MicroDose (MicroDose
Therapeutx)
Next DPI (Chiesi)
Novolizer (Meda)
Oximax (Mantecorp)
Podhaler (Novartis)
Pulmojet (sanofi-aventis)
Pulvinal (Chiesi)
Skyehaler (SKyepharma)
Solis (Sandoz/Novartis)
Taifun (Akela)
Taper Dry (3M)
Trivair (Trimel
Bipharma)
Twincaps/Flowcaps (Hovione)
Twisthaler (Schering /Merck)
Turbuhaler
(AstraZeneca)
Dry Powder Inhalation –
Therapeutic Segment Analysis & Forecasts
Upper Respiratory Indications
Disease Segments
Therapeutic Landscape
Prescribing Trends and
Growth Factors
Systemic Drug Delivery
Bioterror
Diabetes
Hereditary Diseases
Cystic Fibrosis
Infectious Diseases
Osteoporosis
Neurology
Pain Management
Market Factors
Device Design
Regulatory
Issues
Patient Compliance
The Role of
CMOs/CSOs
Healthcare Economics
Company
Profiles
|
|
|
|
|
